People: Sigma-Aldrich Corp (SIAL.OQ)

SIAL.OQ on NASDAQ Stock Exchange Global Select Market

138.86USD
2:02pm EDT
Change (% chg)

$-0.09 (-0.06%)
Prev Close
$139.18
Open
$139.09
Day's High
$139.13
Day's Low
$138.79
Volume
119,053
Avg. Vol
256,194
52-wk High
$139.27
52-wk Low
$97.70

Search Stocks

Summary

Name Age Since Current Position

Barrett Toan

67 2010 Independent Chairman of the Board

Rakesh Sachdev

59 2010 President, Chief Executive Officer, Director

Jan Bertsch

58 2013 Chief Financial Officer, Executive Vice President

Gilles Cottier

56 2013 Executive Vice President, President - SAFC Commercial

Franklin Wicks

61 2013 Executive Vice President; President - Applied

George Miller

60 2009 Senior Vice President, General Counsel, Secretary

Karen Miller

57 2013 Senior Vice President - Corporate Development and Corporate Communications

Michael Kanan

51 2009 Vice President, Corporate Controller

Michael Hollenkamp

2013 Vice President, Treasurer

Douglas Rau

58 2005 Vice President - Human Resources

Rebecca Bergman

58 2008 Independent Director

George Church

60 2009 Independent Director

Michael Marberry

56 2012 Independent Director

W. Lee McCollum

66 2001 Independent Director

Avi Nash

62 2005 Independent Director

Steven Paul

64 2006 Independent Director

J. Pedro Reinhard

69 2011 Independent Director

D. Dean Spatz

70 1994 Independent Director

Quintin Lai

Vice President - Investor Relations and Strategy

Biographies

Name Description

Barrett Toan

Mr. Barrett A. Toan is an Independent Chairman of the Board of Sigma-Aldrich Corporation. Mr. Toan has more than 32 years of healthcare industry experience and more than 29 years of management experience, including more than 20 years as a CEO. He served as Chairman of Express Scripts, Inc. (“Express Scripts”), a pharmacy benefits management company, from 1996 to 2006 and as President and CEO of Express Scripts from 1989 to 2005. As President and CEO, Mr. Toan led the Express Scripts initial public offering in 1992, deployed innovative cost-savings and patient safety programs and led the company’s growth into a Fortune 500 firm. Prior to joining Express Scripts, he was the Chief Operating Officer and Executive Director of Sanus Corps Health Systems Inc. (later GenCare) (“Sanus”), a leading health maintenance organization. Before joining Sanus, Mr. Toan served in the public sector in a variety of roles, including the Director of Missouri’s Department of Social Services. Mr. Toan earned his M.B.A. from The Wharton School of the University of Pennsylvania and A.B. from Kenyon College.

Rakesh Sachdev

Mr. Rakesh Sachdev is President, Chief Executive Officer, Director of Sigma-Aldrich Corporation, since November 2010. Mr. Sachdev joined the Company in 2008 as CFO and took on the additional role of Chief Administrative Officer and direct oversight of the Company’s international business in 2009. He was Senior Vice President and President Asia Pacific of ArvinMeritor, Inc. (“ArvinMeritor”), a global supplier of parts and services to the automotive industry, from March 2007 to July 2008. At ArvinMeritor, Mr. Sachdev also served in other leadership roles, including Interim CFO, Senior Vice President Strategy and Corporate Development and Vice President and General Manager of several of ArvinMeritor’s global businesses from February 1999 to March 2007. Prior to joining ArvinMeritor, he worked for Cummins Inc., a global manufacturer of engines and other industrial products in various leadership roles, including CFO for one of its largest business units, and as Managing Director of its Mexican operations. Mr. Sachdev earned his M.B.A. from Indiana University, holds a Masters in Mechanical Engineering from the University of Illinois and earned his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology in New Delhi. Mr. Sachdev is also a director of Regal-Beloit Corporation and the Federal Reserve Bank of St. Louis and serves on the Board of Trustees of Washington University in St. Louis.

Jan Bertsch

Ms. Jan A. Bertsch is Chief Financial Officer, Executive Vice President of Sigma-Aldrich Corporation, since March 2012. She also served as Treasurer from September 2012 until September 2013. She was previously Vice President, Controller and Principal Accounting Officer of Borg Warner Inc. from August 2011 to February 2012 and Vice President and Treasurer of Borg Warner Inc. from December 2009 to July 2011. From July 2008 to November 2009, Ms. Bertsch was Senior Vice President, Treasurer and Chief Information Officer for Chrysler Group, LLC and Chrysler LLC, and from May 2006 to June 2008, she was Chief Information Officer of Daimler Chrysler's Chrysler Group and Mercedes Benz NAFTA organizations and Chrysler LLC.

Gilles Cottier

Mr. Gilles A. Cottier is Executive Vice President, President - SAFC Commercial of Sigma-Aldrich Corporation, since January 2013. Prior to that, he was President of SAFC since January 2009 and was made an Executive Vice President of the Company in 2011. He served as President of the Research Essentials business unit of the Company from July 2005 until January 2009.

Franklin Wicks

Dr. Franklin D. Wicks, Jr., is Executive Vice President, President - Applied of Sigma-Aldrich Corporation, since January 2013. Prior to that, he was President of Research and has been an Executive Vice President of the Company since February 2011. He previously served as President of the Research Essentials and Specialties business units of the Company from January 2009 to February 2011 and Managing Director-U.S. & Canada from January 2010 to February 2011. Prior to that, he served as President of SAFC for more than five years.

George Miller

Mr. George Lloyd Miller, J.D., is Senior Vice President, General Counsel, Secretary of Sigma-Aldrich Corporation, since October 2009. Prior to that, he served as General Counsel of Novartis Services, Inc. from September 2008 to September 2009, and as General Counsel of Novartis Corporation from December 2005 to August 2008.

Karen Miller

Ms. Karen J. Miller is Senior Vice President - Corporate Development and Corporate Communications of Sigma-Aldrich Corporation, since January 2013. Prior to that, she was Senior Vice President, Strategy & Corporate Development of the Company since May 2009 and was previously Vice President, Strategy & Corporate Development of the Company from January 2009 through May 2009. Prior to that, she served as Controller of the Company for more than five years.

Michael Kanan

Mr. Michael F. Kanan is Vice President, Corporate Controller of Sigma-Aldrich Corporation, since April 2009. Prior to that, he served as Vice President Finance-Light Vehicle Systems of ArvinMeritor from October 2006 to April 2009.

Michael Hollenkamp

Mr. Michael Hollenkamp has been appointed as Vice President, Treasurer of Sigma-Aldrich Corporation with effect from September 15, 2013. Mr. Hollenkamp has been with Sigma-Aldrich since 1997 and has held various leadership positions within the Company's Tax and Treasury Departments. Prior to joining the Company, he held tax positions with two other Saint Louis-based companies. Mr. Hollenkamp has an Accounting Degree from Southern Illinois University at Edwardsville and is a Certified Public Accountant.

Douglas Rau

Mr. Douglas W. Rau is Vice President - Human Resources of Sigma-Aldrich Corporation, since October 2005. He served as Vice President Human Resources of Kellwood Company from 2002 to 2005.

Rebecca Bergman

Ms. Rebecca M. Bergman is an Independent Director of Sigma-Aldrich Corporation. Ms. Bergman has more than 27 years of experience in the medical technology industry including over 19 years of experience in research and technology management and product development. Ms. Bergman has served as President of Gustavus Adolphus College, a liberal arts college located in St. Peter, MN since 2014. Previously, Ms. Bergman served as Vice President, Research and Technology for Cardiac Rhythm Disease Management (CRDM) of Medtronic, Inc. (“Medtronic”), a manufacturer of products and therapies used in the diagnosis, treatment and monitoring of chronic medical conditions, from May 2012 to April 2014. She previously served as Vice President, New Therapies and Diagnostics, for CRDM of Medtronic from February 2009 to May 2012, and as Vice President, Science and Technology of Medtronic from April 2002 to February 2009. She has served as a member of the National Advisory Committee of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH) and currently serves on a number of academic advisory boards. Ms. Bergman is a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a member of the National Academy of Engineering (NAE). She has a B.S. in Chemical Engineering from Princeton University and an honorary Ph.D. in Engineering from Drexel University. She has also completed graduate studies in Chemical Engineering and Material Science at the University of Minnesota.

George Church

Dr. George M. Church, Ph.D., is an Independent Director of Sigma-Aldrich Corporation. Dr. Church is a leading expert in human genetics and biotechnology and has significant academic research institution experience, having served as a Professor of Genetics at Harvard Medical School since 1986. He concurrently acts as Director of the Center for Computational Genetics at Harvard Medical School, where he has directed laboratory research in DNA sequencing, synthesis and homologous recombination. Dr. Church, an initiator of the Personal Genome Project in 2005 and a leader in the field of synthetic biology, is a director at the U.S. Department of Energy Center on Bioenergy at Harvard University, as well as the National Institutes of Health Center of Excellence in Genomic Science at Harvard University. Dr. Church has served in scientific advisory roles for more than 20 companies in the field of DNA technology, diagnostics and biofuels. He earned his Ph.D. in Biochemistry and Molecular Biology from Harvard University and his B.A. in Zoology and Chemistry from Duke University.

Michael Marberry

Mr. Michael L. Marberry is an Independent Director of Sigma-Aldrich Corp. Mr. Marberry has more than 32 years of management experience, including more than 17 years with J. M. Huber Corporation (“Huber”), a company that manufactures and sells products in the fields of specialty chemicals and engineered materials. He has served as President and CEO since 2009. Mr. Marberry served as President of Huber Engineered Materials, a division of Huber, from 2006 to 2009, CFO of Huber from 2002 to 2006, and Corporate Vice President of Strategy and New Business Development for Huber from 1997 to 2002. Prior to joining Huber, he served in senior roles at M.A. Hanna Company, a specialty polymers company in Cleveland, Ohio, and in various roles with McKinsey & Company, Inc. and The Proctor and Gamble Company. Mr. Marberry is an audit committee financial expert. He is a director of Huber and a National Association of Corporate Directors (NACD) Governance Fellow. Mr. Marberry earned his M.B.A. from Amos Tuck School of Business Administration at Dartmouth College and his M.S. and B.S. in Chemical Engineering from the University of Kentucky.

W. Lee McCollum

Mr. W. Lee McCollum is an Independent Director of Sigma-Aldrich Corporation. At S.C. Johnson. Mr. McCollum is an audit committee financial expert and has significant management experience including more than 35 years of experience with S.C. Johnson & Son, Inc. (“S.C. Johnson”), a global manufacturer and marketer of consumer products, where he held positions involving accounting, treasury, tax, internal audit, mergers and acquisitions, strategic planning, personnel matters, international operations and general management. At S.C. Johnson, he served as Senior Vice President and CFO from 1997 to 2004 and as Executive Vice President and CFO from 2005 to 2009. From 2005 to 2009, his responsibilities also included global manufacturing. Mr. McCollum retired in 2009. Mr. McCollum is also a director of Johnson Outdoors, Inc., Coastal South Bancshares, Inc. (Risk Management Committee Chair), and Johnson Financial Group, a large private regional bank holding company (Compensation Committee member, Risk Oversight Committee Chair). He earned his M.B.A. from Harvard University and B.S. from the University of Idaho.

Avi Nash

Mr. Avi M. Nash is an Independent Director of Sigma-Aldrich Corporation. Mr. Nash has more than 37 years of experience in the chemical and financial services sectors. He is the Founder of Avi Nash LLC, a management consulting firm that focuses on strategy, mergers and acquisitions and capital market transactions for the chemical industry, which he founded in 2003, as well as the Managing Director of Indian River Advisors Corporation, a financial advisory firm, since 2013. Earlier, he was a partner of Goldman Sachs & Co. (“Goldman Sachs”), where he led the global chemical industry team in investment research, consistently topping performance rankings in the U.S. and globally. At Goldman Sachs, Mr. Nash was appointed Vice President in 1989 and Managing Director in 1996, elected a partner in 1998 and named an advisory director in 2002. Prior to Goldman Sachs, he gained over 10 years of experience involving business strategy at Booz Allen and Hamilton, as well as R&D, engineering, marketing and strategic planning at UOP Inc., a global leader in petroleum refining technology. He has a Master of Management degree from Northwestern University, an M.S. degree in Chemical Engineering from Syracuse University and was named a distinguished alumnus of the Indian Institute of Technology, Bombay, where he received a Bachelor’s degree in Chemical Engineering. He is a Trustee of Connecticut-based Indira Foundation. Mr. Nash is an audit committee financial expert.

Steven Paul

Dr. Steven M. Paul, M.D., is an Independent Director of Sigma-Aldrich Corporation. Dr. Paul is President and CEO of Voyager Therapeutics, Inc., a gene therapy company, a position he has held since September 2014, and an adjunct Professor of Neurology (Neuroscience), Psychiatry and Pharmacology at Weill Cornell Medical College of Cornell University. He has more than 21 years of management experience in the pharmaceutical and biotechnology industries and 38 years of scientific research experience. Dr. Paul retired in 2010 as Executive Vice President for Science and Technology and President of the Lilly Research Laboratories of Eli Lilly and Company (“Lilly”), a pharmaceutical company that engages in the discovery, development, manufacture and sale of pharmaceutical products, positions he held since 2003. He joined Lilly in 1993 and served in roles of increasing responsibility within the Lilly research organization, including Vice President of Discovery Research and Clinical Investigation. Prior to joining Lilly, Dr. Paul served in several senior roles at the National Institute of Mental Health, including serving as the Scientific Director of the Intramural Research Program. He has authored or coauthored more than 500 papers and invited book chapters and serves on the editorial boards of numerous scientific journals and as a grant reviewer for several extramural and intramural committees. He is a director of Alnylam Pharmaceuticals and Sage Therapeutics, Inc. and a Venture Partner at Third Rock Ventures. He is also a director of the Foundation of the National Institutes of Health, a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science. Dr. Paul holds M.D., M.S. and B.A. degrees from Tulane University.

J. Pedro Reinhard

Mr. J. Pedro Reinhard is an Independent Director of Sigma-Aldrich Corporation. Mr. Reinhard has more than 38 years of experience in the chemical industry and more than 33 years of international management experience, including more than 10 years as a CFO of a publicly traded company. He is an audit committee financial expert and has significant capital markets and finance experience. Mr. Reinhard has served as President of Reinhard and Associates, a financial advisory practice, since 2006. He served as Executive Vice President and CFO of The Dow Chemical Company (“Dow”), a manufacturer of chemicals, plastic materials, agricultural and other specialized products, from 1995 to 2005. Previously, Mr. Reinhard held a variety of senior international, financial and operating leadership positions at Dow, including senior operations assignments in Europe, after beginning his career at Dow in 1970 in Brazil. In 1988, he was appointed Treasurer of Dow. Mr. Reinhard served as a director of Dow from 1995 to 2007. Mr. Reinhard is also a director of Colgate Palmolive Co. and Royal Bank of Canada. He earned his M.B.A. from Getulio Vargas University, São Paulo, and has done postgraduate work at the University of Cologne, Germany, and Stanford University.

D. Dean Spatz

Mr. D. Dean Spatz is an Independent Director of Sigma-Aldrich Corporation. Mr. Spatz has more than 46 years of management experience, including more than 32 years as a CEO of a publicly traded company. He currently serves as CEO of Watasso Ventures, a company that specializes in investing in and actively participating in the management and development of entrepreneurial start-up companies, a position he has held since 2003. In that capacity, he serves on the boards of four portfolio companies in various technical fields. Previously, Mr. Spatz served as Chairman and CEO of Osmonics, Inc. (NYSE listed company), an international manufacturer and marketer of water purification, fluid separation and sea water handling products and equipment; a company he founded in 1969. He left Osmonics in 2003 after the company was acquired by GE Infrastructure, a unit of General Electric Company. Mr. Spatz is a licensed chemical engineer and is extensively published on reverse osmosis membrane technology, a breakthrough that he pioneered. Mr. Spatz earned his M.S. in Engineering Management, B.S. in Engineering and B.A. from Dartmouth College.

Quintin Lai

Search Stocks